Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
NCT07061080 · Grupo Espanol de Tumores Neuroendocrinos · PHASE2 · terminated · last registry update 2026-09-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.” | – | Registry record, Grupo Espanol de Tumores Neuroendocrinos |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: Genmab, Epcoritamab + Investigator's Choice Chemotherapy (NCT07226752)
- 2026-11-03Results posted on the registry: Genmab, Epcoritamab + Investigator's Choice Chemotherapy (NCT04628494)
- 2026-10-28Results posted on the registry: Washington University School of Medicine, Mosunetuzumab + Polatuzumab vedotin (NCT05410418)
- 2026-10-23Also stopped (terminated): Genmab, Epcoritamab + Lenalidomide (NCT05660967)
- 2026-10-22Phase 3 first posted: Alliance for Clinical Trials in Oncology, Daratumumab and Recombinant Human Hyaluronidase + Lenalidomide (NCT07887984)
- 2026-10-08Also stopped (suspended): M.D. Anderson Cancer Center, Blinatumomab (NCT07192237)
- 2026-10-07Also stopped (suspended): City of Hope Medical Center, Talquetamab (NCT06572605)
- 2026-09-25Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab (NCT02458014)
- 2026-08-21Phase 3 first posted: Amgen, Tarlatamab (NCT07778316)
- 2026-08-18Results posted on the registry: Hoffmann-La Roche, Glofitamab + Tocilizumab (NCT04980222)
- 2026-08-17Also stopped (terminated): Regeneron Pharmaceuticals, REGN7041 (NCT07218770)
- 2026-07-31Phase 3 first posted: Polish Myeloma Consortium, Teclistamab + Talquetamab (NCT07740486)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-07-24Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cyclophosphamide (NCT07724457)
- 2026-07-23Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, BLB101 for Injection + Blinatumomab for Injection (NCT07723911)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-16Phase 3 first posted: University of Leeds, Daratumumab + Lenalidomide (NCT07649525)
- 2026-06-09Phase 3 first posted: PrECOG, LLC., Tarlatamab + Durvalumab (NCT07637513)
- 2026-06-09Results posted on the registry: University of California, Davis, Blinatumomab + Ibrutinib (NCT02997761)
- 2026-05-13Results posted on the registry: University of Washington, Mosunetuzumab + Obinutuzumab (NCT05169658)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-05-06Also stopped (terminated): Pfizer, maplirpacept (PF-07901801) + Glofitamab (NCT05896163)
- 2026-04-28Also stopped (withdrawn): National Cancer Institute (NCI), Tarlatamab + Sacituzumab Govitecan (NCT07328490)
- 2026-04-24Also stopped (terminated): Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision